Home・Stock List・BioCryst Pharmaceuticals Inc

BioCryst Pharmaceuticals Inc

Closed

SectorHealthcare

9.34 -0.21

Buy Sell

Overview

Share price change

24h

Current

Min

9.33

Max

9.42

Key metrics
By Trading Economics
Income	-1.1B -722M
Sales	-250M 156M
P/E Sector Avg	7.603 62.58
EPS	0.14
Profit margin	-461.478
Employees	435
EBITDA	-966M -700M

Recommendations
By TipRanks
Recommendations	Strong Buy
12 Months Forecast	+134.37% upside

Dividends
By Acuity
Next Earnings	5 Aug 2026

Market Stats
By TradingEconomics
Market Cap	-22M 2.3B
Previous open	9.55
Previous close	9.34

News Sentiment

By Acuity

76%

24%

306 / 340 Healthcare

BioCryst Pharmaceuticals Inc Chart

Past performance is not a reliable indicator of future results.

Related News

24 Jul 2026, 21:01 UTC

BioCryst Pharmaceuticals Inc. shares are lower in after-market hours, reflecting broader market trends following a decline in the Nasdaq influenced by negative earnings reports.

22 Jul 2026, 21:51 UTC

BioCryst Pharmaceuticals Inc shares are lower in after-market trading, continuing a decline amid significant volatility in U.S. markets and lack of specific news.

21 Jul 2026, 17:46 UTC

BioCryst Pharmaceuticals Inc shares are higher today, continuing an upward trend since Monday. The stock remains below its 20-day moving average.

20 Jul 2026, 19:16 UTC

Correlated Moves

Shares lower amid decline in Biotechnology sub-sector and SPDR ETF.

Peer Comparison

Price change

BioCryst Pharmaceuticals Inc Forecast

Price Target

By TipRanks

134.37% upside

12 Months Forecast

Average 21.89 USD 134.37%

High 32 USD

Low 12 USD

Based on 9 Wall Street analysts offering 12 month price targets forBioCryst Pharmaceuticals Inc - Dist in the last 3 months.

Rating Consensus

By TipRanks

Strong Buy

9 ratings

Buy

Hold

Sell

Based on 9 analysts giving stock ratings to BioCryst Pharmaceuticals Inc - Dist in the past 3 months.

Sentiment

By Acuity

306 / 340 Healthcare

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

About BioCryst Pharmaceuticals Inc

BioCryst Pharmaceuticals, Inc., a biotechnology company, develops oral small-molecule and protein therapeutics to treat rare diseases. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat hereditary angioedema. It is also developing BCX10013, an oral factor D inhibitor for complement-mediated diseases. The company has collaborations and in-license relationships with the Torii Pharmaceutical Co., Ltd.; Seqirus UK Limited; Shionogi & Co., Ltd.; Green Cross Corporation; National Institute of Allergy and Infectious Diseases; Biomedical Advanced Research and Development Authority; the U.S. Department of Health and Human Services; and The University of Alabama at Birmingham, as well as Albert Einstein College of Medicine of Yeshiva University and Industrial Research, Ltd. BioCryst Pharmaceuticals, Inc. was founded in 1986 and is headquartered in Durham, North Carolina.